| Targeting CDK9 reactivates epigenetically silenced genes in cancer H Zhang, S Pandey, M Travers, H Sun, G Morton, J Madzo, W Chung, ... Cell 175 (5), 1244-1258. e26, 2018 | 200 | 2018 |
| Interferon-γ signaling in melanocytes and melanoma cells regulates expression of CTLA-4 X Mo, H Zhang, S Preston, K Martin, B Zhou, N Vadalia, AM Gamero, ... Cancer research 78 (2), 436-450, 2018 | 103 | 2018 |
| Repositioning FDA-approved drugs in combination with epigenetic drugs to reprogram colon cancer epigenome NJM Raynal, EM Da Costa, JT Lee, V Gharibyan, S Ahmed, H Zhang, ... Molecular cancer therapeutics 16 (2), 397-407, 2017 | 71 | 2017 |
| Transcriptional selectivity of epigenetic therapy in cancer T Sato, M Cesaroni, W Chung, S Panjarian, A Tran, J Madzo, Y Okamoto, ... Cancer research 77 (2), 470-481, 2017 | 60 | 2017 |
| Selective CDK9 inhibition by natural compound toyocamycin in cancer cells S Pandey, R Djibo, A Darracq, G Calendo, H Zhang, RA Henry, ... Cancers 14 (14), 3340, 2022 | 11 | 2022 |
| Comparative modeling of CDK9 Inhibitors to explore selectivity and structure-activity relationships P Kirubakaran, G Morton, P Zhang, H Zhang, J Gordon, M Abou-Gharbia, ... bioRxiv, 2020.06. 08.138602, 2020 | 4 | 2020 |
| Engineering of Chimeric Antigen Receptor T Cells with integrin αEβ7 Results in Augmented Therapeutic Efficacy against E-cadherin positive tumor H Sun, S He, L Meng, Y Wang, H Zhang, Y Liu, J Wang, M Tao, SK Barta, ... BioRxiv, 727446, 2019 | 1 | 2019 |
| Engineering of CD19-Specific Chimeric Antigen Receptor T Cells With the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model H Sun, S He, L Meng, Y Wang, H Zhang, Y Liu, J Wang, M Tao, SK Barta, ... Blood 132, 2050, 2018 | 1 | 2018 |
| Identifying novel potential epigenetic anti-cancer drugs from natural compounds using a phenotypic-based screening H Zhang, NJM Raynal, T Sato, Y Okamoto, J Garriga, B Garcia, G Morton, ... Cancer Research 77 (13_Supplement), 5064-5064, 2017 | 1 | 2017 |
| A phenotypic cell-based screen to identify novel potential epigenetic anti-cancer drugs from natural compounds H Zhang, NJM Raynal, T Sato, Y Okamoto, J Garriga, G Morton, ... Cancer Research 76 (14_Supplement), 4701-4701, 2016 | 1 | 2016 |
| MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer H Zhang, C Huang, J Gordon, S Yu, G Morton, W Childers, ... Clinical Epigenetics 16 (1), 3, 2024 | | 2024 |
| Aminothiazole compounds and methods using same JPJ Issa, H Zhang, M Abou-Gharbia, WE Childers, GC Morton US Patent 11,787,794, 2023 | | 2023 |
| Bridged bicycloalkyl-substituted aminothiazoles and their methods of use WC Childers, MA Abou-Gharbia, GC Morton, JPJ Issa, H Zhang US Patent 10,941,126, 2021 | | 2021 |
| Aminothiazole compounds and methods using same JPJ Issa, H Zhang, M Abu-Gharbia, WE Childers, GC Morton US Patent 10,513,516, 2019 | | 2019 |
| CDK9 phosphorylates BRG1 chromatin remodeler S Pandey, H Zhang, CA Barrero, S Merali, X Graña, JP Issa Cancer Research 78 (13_Supplement), 2995-2995, 2018 | | 2018 |
| Target specificity of epigenetic therapy in cancer T Sato, M Cesaroni, S Panjarian, A Tran, J Madzo, Y Okamoto, H Zhang, ... Cancer Research 76 (14_Supplement), 2657-2657, 2016 | | 2016 |
| Abstract B42: Decitabine specifically targets genes that gain DNA methylation and lose expression in cancer and can be combined with histone methylation inhibitors for … T Sato, M Cesaroni, A Tran, J Madzo, Y Okamoto, H Zhang, S Panjarian, ... Cancer Research 76 (2_Supplement), B42-B42, 2016 | | 2016 |
| Abstract B50: A phenotypic screen to identify novel potential epigenetic anticancer drugs from natural compounds H Zhang, NJM Raynal, T Sato, Y Okamoto, B Garcia, G Morton, ... Cancer Research 76 (2_Supplement), B50-B50, 2016 | | 2016 |
| A phenotypic screen to discover novel epigenetic anticancer drugs from natural compounds H Zhang, N Raynal, T Sato, Y Okamoto, R Henry, AJ Andrews, G Morton, ... Cancer Research 75 (15_Supplement), 3519-3519, 2015 | | 2015 |
| Discovering potential epigenetic anti-cancer drugs derived from natural compounds H Zhang, NJM Raynal, MA Jacobson, JP Issa Cancer Research 74 (19_Supplement), 378-378, 2014 | | 2014 |
